{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T10:46:49Z","timestamp":1775126809326,"version":"3.50.1"},"reference-count":107,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["613690173"],"award-info":[{"award-number":["613690173"]}]},{"award":["613690173"],"award-info":[{"award-number":["613690173"]}],"id":[{"id":"https:\/\/ror.org\/00snfqn58","id-type":"ROR","asserted-by":"publisher"}]},{"name":"MedInUP"},{"DOI":"10.13039\/501100011929","name":"FEDER","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-032188"],"award-info":[{"award-number":["POCI-01-0145-FEDER-032188"]}],"id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["PTDC\/MEC-CAR\/32188\/2017"],"award-info":[{"award-number":["PTDC\/MEC-CAR\/32188\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"award":["PTDC\/MEC-CAR\/32188\/2017"],"award-info":[{"award-number":["PTDC\/MEC-CAR\/32188\/2017"]}],"id":[{"id":"https:\/\/ror.org\/00snfqn58","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Annexin A1 (ANXA1) is a proresolving protein regulated by glucocorticoids, the standard care for severe and critical COVID-19 patients. As part of a larger project including hospitalized COVID-19 patients, this study aimed at evaluating ANXA1 and its FPR2 receptor in these patients, focusing on longitudinal profiles and comparison across disease severities and outcomes, and exploring their correlations with inflammation, endotheliitis and other proresolving mediators. Blood was collected in \u201csevere\u201d (n = 27), \u201ccritical\u201d (n = 17) and \u201ccritical on veno-venous extracorporeal membrane oxygenation\u201d (n = 17) COVID-19 patients at admission, days 3\u20134, 5\u20138, and weekly thereafter, and in controls (n = 23) at a single time point. We quantified ANXA1, resolvin D1, resolvin E1 (RvE1) and endocan by ELISA, cytokines and other endothelial markers by multiplex immunoassays, and FPR2 and Chemerin1 receptors by RT-qPCR. Most patients underwent a 10-day dexamethasone regimen. Admission ANXA1 and FPR2 were significantly higher in all patient groups. Throughout hospitalization, ANXA1 increased mainly in \u201csevere\u201d patients and survivors, becoming higher at weeks 3 and 4 in survivors versus non-survivors. Variable cumulative dexamethasone doses did not differentially affect ANXA1 or FPR2. ANXA1 was associated with higher RvE1 during the dexamethasone effect period. Exploratory analyses showed that ANXA1 inversely correlated with RvE1 receptor and endotheliitis, whereas both ANXA1 and FPR2 positively correlated with inflammation. In conclusion, ANXA1 may be involved in COVID-19 recovery processes, and its interplay with RvE1 may ameliorate hyperinflammation.<\/jats:p>","DOI":"10.3390\/biom16040508","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:40:52Z","timestamp":1774878052000},"page":"508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Annexin A1 and Dexamethasone Treatment in Hospitalized COVID-19 Patients: Impact on Disease Recovery and Evidence for an Interplay Between Proresolving Mediators"],"prefix":"10.3390","volume":"16","author":[{"given":"Carolina","family":"Silva-Pereira","sequence":"first","affiliation":[{"name":"RISE-Health, Departamento de Biomedicina\u2013Unidade de Farmacologia e Terap\u00eautica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Unidade de Investiga\u00e7\u00e3o em Epidemiologia (EPIUnit), Instituto de Sa\u00fade P\u00fablica da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal"}]},{"given":"Marta","family":"Reina-Couto","sequence":"additional","affiliation":[{"name":"RISE-Health, Departamento de Biomedicina\u2013Unidade de Farmacologia e Terap\u00eautica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Servi\u00e7o de Medicina Intensiva, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Servi\u00e7o de Farmacologia Cl\u00ednica, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"given":"Patr\u00edcia","family":"Pereira-Terra","sequence":"additional","affiliation":[{"name":"Departamento de Biomedicina\u2013Unidade de Farmacologia e Terap\u00eautica, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Pl\u00e1cido da Costa, S\/N, Edif\u00edcio Poente, Piso 3, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-9010","authenticated-orcid":false,"given":"Lu\u00edsa","family":"Teixeira-Santos","sequence":"additional","affiliation":[{"name":"Departamento de Biomedicina\u2013Unidade de Farmacologia e Terap\u00eautica, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Pl\u00e1cido da Costa, S\/N, Edif\u00edcio Poente, Piso 3, 4200-450 Porto, Portugal"},{"name":"iNOVA4Health, NOVA Medical School (NMS), Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria 130, 1169-056 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6813-314X","authenticated-orcid":false,"given":"Sandra","family":"Martins","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Epidemiologia (EPIUnit), Instituto de Sa\u00fade P\u00fablica da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal"},{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Laborat\u00f3rio para a Investiga\u00e7\u00e3o Integrativa e Translacional em Sa\u00fade Populacional (ITR), Rua das Taipas 135, 4050-600 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6965-8597","authenticated-orcid":false,"given":"Dora","family":"Pinho","sequence":"additional","affiliation":[{"name":"RISE-Health, Departamento de Biomedicina\u2013Unidade de Farmacologia e Terap\u00eautica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-6117","authenticated-orcid":false,"given":"Miguel Luz","family":"Soares","sequence":"additional","affiliation":[{"name":"Departamento de Biomedicina\u2013Unidade de Biologia Experimental, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Pl\u00e1cido da Costa, S\/N, Edif\u00edcio Poente, Piso 4, 4200-450 Porto, Portugal"},{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9356-3272","authenticated-orcid":false,"given":"Cl\u00e1udia Camila","family":"Dias","sequence":"additional","affiliation":[{"name":"RISE-Health, Departamento de Medicina da Comunidade, Informa\u00e7\u00e3o e Decis\u00e3o em Sa\u00fade (MEDCIDS), Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Departamento de Recursos Comuns\u2013Unidade de Gest\u00e3o de Conhecimento, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"given":"Ant\u00f3nio","family":"Sarmento","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Doen\u00e7as Infecciosas, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Departamento de Medicina, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-2197","authenticated-orcid":false,"given":"Margarida","family":"Tavares","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Epidemiologia (EPIUnit), Instituto de Sa\u00fade P\u00fablica da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal"},{"name":"Servi\u00e7o de Doen\u00e7as Infecciosas, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-6311","authenticated-orcid":false,"given":"Jo\u00e3o Tiago","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Epidemiologia (EPIUnit), Instituto de Sa\u00fade P\u00fablica da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal"},{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Laborat\u00f3rio para a Investiga\u00e7\u00e3o Integrativa e Translacional em Sa\u00fade Populacional (ITR), Rua das Taipas 135, 4050-600 Porto, Portugal"},{"name":"Departamento de Biomedicina\u2014Unidade de Bioqu\u00edmica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4323-0220","authenticated-orcid":false,"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Medicina Intensiva, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Departamento de Medicina, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-2336","authenticated-orcid":false,"given":"S\u00f3nia","family":"Fraga","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Epidemiologia (EPIUnit), Instituto de Sa\u00fade P\u00fablica da Universidade do Porto, Rua das Taipas 135, 4050-600 Porto, Portugal"},{"name":"Departamento de Biomedicina\u2013Unidade de Farmacologia e Terap\u00eautica, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Pl\u00e1cido da Costa, S\/N, Edif\u00edcio Poente, Piso 3, 4200-450 Porto, Portugal"},{"name":"Laborat\u00f3rio para a Investiga\u00e7\u00e3o Integrativa e Translacional em Sa\u00fade Populacional (ITR), Rua das Taipas 135, 4050-600 Porto, Portugal"},{"name":"Departamento de Sa\u00fade Ambiental, Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge, Rua Alexandre Herculano 321, 4000-055 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-2953","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Albino-Teixeira","sequence":"additional","affiliation":[{"name":"RISE-Health, Departamento de Biomedicina\u2013Unidade de Farmacologia e Terap\u00eautica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"given":"Roberto","family":"Roncon-Albuquerque","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Medicina Intensiva, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7230-5020","authenticated-orcid":false,"given":"Teresa","family":"Sousa","sequence":"additional","affiliation":[{"name":"RISE-Health, Departamento de Biomedicina\u2013Unidade de Farmacologia e Terap\u00eautica, Faculdade de Medicina da Universidade do Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.idc.2022.01.003","article-title":"COVID-19 Pathogenesis and Clinical Manifestations","volume":"36","author":"Marcelin","year":"2022","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_2","unstructured":"WHO (2021). Clinical Management of COVID-19: Living Guidance, 25 January 2021, World Health Organization. WHO\/2019-nCoV\/clinical\/2021.1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8671713","DOI":"10.1155\/2021\/8671713","article-title":"Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19-Mechanisms and Therapeutic Targets","volume":"2021","author":"Fodor","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Niedzwiedzka-Rystwej, P., Majchrzak, A., Kurkowska, S., Malkowska, P., Sierawska, O., Hrynkiewicz, R., and Parczewski, M. (2022). Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094545"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10555-020-09889-4","article-title":"Inflammation resolution: A dual-pronged approach to averting cytokine storms in COVID-19?","volume":"39","author":"Panigrahy","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/bph.15164","article-title":"Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19?","volume":"177","author":"Sousa","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2019.01.007","article-title":"Mediators of the Resolution of the Inflammatory Response","volume":"40","author":"Sugimoto","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.tips.2015.07.007","article-title":"Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation","volume":"36","author":"Perretti","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1161\/CIRCRESAHA.121.319142","article-title":"Disrupted Resolution Mechanisms Favor Altered Phagocyte Responses in COVID-19","volume":"129","author":"Koenis","year":"2021","journal-title":"Circ. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/infdis\/jiab632","article-title":"Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients with Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate with Markers of the Adaptive Immune Response","volume":"225","author":"Turnbull","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101982","DOI":"10.1016\/j.redox.2021.101982","article-title":"Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19","volume":"43","author":"Dominic","year":"2021","journal-title":"Redox Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00011-022-01682-z","article-title":"Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients","volume":"72","author":"Martins","year":"2023","journal-title":"Inflamm. Res."},{"key":"ref_13","unstructured":"Bhimraj, A., Falck-Ytter, Y., Baden, L.R., Bedimo, R., Cheng, V.C.C., Chew, K.W., Chiotos, K., Daar, E.S., Dzierba, A.L., and Glidden, D.V. (2025, October 18). IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (October 2025). Available online: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/."},{"key":"ref_14","unstructured":"WHO (2025). Therapeutics and COVID-19: Living Guideline, August 2025, World Health Organization."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/278456a0","article-title":"Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation","volume":"278","author":"Flower","year":"1979","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/bjp.2008.252","article-title":"Annexin-A1: A pivotal regulator of the innate and adaptive immune systems","volume":"155","author":"Perretti","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gavins, F.N., and Hickey, M.J. (2012). Annexin A1 and the regulation of innate and adaptive immunity. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00354"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1476-5381.2009.00483.x","article-title":"Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics","volume":"158","author":"Perretti","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.bbalip.2016.03.022","article-title":"A novel anti-inflammatory mechanism of high density lipoprotein through up-regulating annexin A1 in vascular endothelial cells","volume":"1861","author":"Pan","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1515\/hsz-2016-0200","article-title":"Annexin A1 and resolution of inflammation: Tissue repairing properties and signalling signature","volume":"397","author":"Gobbetti","year":"2016","journal-title":"Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bruschi, M., Petretto, A., Vaglio, A., Santucci, L., Candiano, G., and Ghiggeri, G.M. (2018). Annexin A1 and Autoimmunity: From Basic Science to Clinical Applications. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051348"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri2470","article-title":"Annexin A1 and glucocorticoids as effectors of the resolution of inflammation","volume":"9","author":"Perretti","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nrrheum.2013.126","article-title":"Annexin A1: Potential for glucocorticoid sparing in RA","volume":"9","author":"Yang","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bbrc.2006.08.179","article-title":"Glucocorticoid upregulation of the annexin-A1 receptor in leukocytes","volume":"349","author":"Sawmynaden","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1111\/bph.15919","article-title":"Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35","volume":"179","author":"Qin","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.1003145","article-title":"Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2\/lipoxin A4 receptor and operative in the inflamed microvasculature","volume":"186","author":"Brancaleone","year":"2011","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14530","DOI":"10.1073\/pnas.1410851111","article-title":"Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway","volume":"111","author":"Fredman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmet.2015.05.003","article-title":"Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease","volume":"22","author":"Borgeson","year":"2015","journal-title":"Cell Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s10753-016-0364-9","article-title":"Resolvin D1 Alleviates the Lung Ischemia Reperfusion Injury via Complement, Immunoglobulin, TLR4, and Inflammatory Factors in Rats","volume":"39","author":"Zhao","year":"2016","journal-title":"Inflammation"},{"key":"ref_30","unstructured":"IUPHAR\/BPS (2025, April 27). IUPHAR\/BPS Guide to PHARMACOLOGY. Resolvin E1. Available online: https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?tab=biology&ligandId=3333."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ni.1627","article-title":"Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation","volume":"9","author":"Haworth","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14728222.2017.1364363","article-title":"Annexin A1 and specialized proresolving lipid mediators: Promoting resolution as a therapeutic strategy in human inflammatory diseases","volume":"21","author":"Perucci","year":"2017","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"111033","DOI":"10.1016\/j.biopha.2020.111033","article-title":"Exploiting the pro-resolving actions of glucocorticoid-induced proteins Annexin A1 and GILZ in infectious diseases","volume":"133","author":"Vago","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1172\/JCI77014","article-title":"Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection","volume":"125","author":"Tzelepis","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.imbio.2014.12.001","article-title":"Absence of Annexin A1 impairs host adaptive immunity against Mycobacterium tuberculosis in vivo","volume":"220","author":"Vanessa","year":"2015","journal-title":"Immunobiology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1096\/fj.201902172R","article-title":"The Annexin A1\/FPR2 pathway controls the inflammatory response and bacterial dissemination in experimental pneumococcal pneumonia","volume":"34","author":"Machado","year":"2020","journal-title":"FASEB J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1042\/CS20255801","article-title":"Annexin A1 as a key modulator of lung inflammation during coronavirus infections","volume":"139","author":"Resende","year":"2025","journal-title":"Clin. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e70111","DOI":"10.1002\/iid3.70111","article-title":"The Protective Effects of Annexin A1 in Acute Lung Injury Mediated by Nrf2","volume":"13","author":"Huang","year":"2025","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e371203","DOI":"10.1590\/acb371203","article-title":"Annexin A1 peptide Ac2-26 mitigates ventilator-induced lung injury in acute respiratory distress syndrome rats and partly depended on the endothelial nitric oxide synthase pathway","volume":"37","author":"Ju","year":"2023","journal-title":"Acta Cir. Bras."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/07853890.2021.1925149","article-title":"Ac2-26 mitigated acute respiratory distress syndrome rats via formyl peptide receptor pathway","volume":"53","author":"Ju","year":"2021","journal-title":"Ann. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"120614","DOI":"10.1016\/j.lfs.2022.120614","article-title":"Differential expression of genes regulated by the glucocorticoid receptor pathway in patients with pulmonary tuberculosis","volume":"301","author":"Gallucci","year":"2022","journal-title":"Life Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/cdd.2016.19","article-title":"Influenza A virus enhances its propagation through the modulation of Annexin-A1 dependent endosomal trafficking and apoptosis","volume":"23","author":"Arora","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e73853","DOI":"10.7554\/eLife.73853","article-title":"Targeting the Annexin A1-FPR2\/ALX pathway for host-directed therapy in dengue disease","volume":"11","author":"Costa","year":"2022","journal-title":"Elife"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1559-0275-10-14","article-title":"Proteomic profiling of serum samples from chikungunya-infected patients provides insights into host response","volume":"10","author":"Puttamallesh","year":"2013","journal-title":"Clin. Proteom."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jcma.2013.05.004","article-title":"Plasma levels in sepsis patients of annexin A1, lipoxin A4, macrophage inflammatory protein-3a, and neutrophil gelatinase-associated lipocalin","volume":"76","author":"Tsai","year":"2013","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gu, M., Han, X., Liu, X., Sui, F., Zhang, Q., and Pan, S. (2023). Predictive Value of Annenxin A1 for Disease Severity and Prognosis in Patients with Community-Acquired Pneumonia. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030396"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhou, F., Chen, M., Liu, Y., Xia, X., and Zhao, P. (2024). Serum mitochondrial-encoded NADH dehydrogenase 6 and Annexin A1 as novel biomarkers for mortality prediction in critically ill patients with sepsis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1486322"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Santana, B.B., Queiroz, M.A.F., Cerveira, R.A., Rodrigues, C.M., da Silva Graca Amoras, E., da Costa, C.A., de Sousa, M.S., Ishak, R., Goulart, L.R., and Vallinoto, A.C.R. (2021). Low Annexin A1 level in HTLV-1 infected patients is a potential biomarker for the clinical progression and diagnosis of HAM\/TSP. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05917-y"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"152728","DOI":"10.1016\/j.imbio.2023.152728","article-title":"Tissue plasminogen activator receptor ANXA2 and its complementary regulator anti-inflammatory ANXA1 as prognostic indicators of inflammatory response in COVID-19 pathogenesis","volume":"228","author":"Shenoy","year":"2023","journal-title":"Immunobiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e14606","DOI":"10.1111\/ijcp.14606","article-title":"Annexin A1 as a potential prognostic biomarker for COVID-19 disease: Case-control study","volume":"75","author":"Canacik","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5578\/mb.20229903","article-title":"Evaluation of Annexin-1 (ANXA-1), Annexin-2 (ANXA-2) and Bone Morphogenetic Protein-7 (BMP-7) Serum Levels in Patients Followed Up with A Diagnosis of COVID-19","volume":"56","author":"Ural","year":"2022","journal-title":"Mikrobiyol. Bul."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Busch, M.H., Timmermans, S., Aendekerk, J.P., Ysermans, R., Amiral, J., Damoiseaux, J., Reutelingsperger, C.P., and Paassen, P.V. (2022). Annexin A1 Is Associated with Adverse Clinical Outcomes in Patients with COVID-19. J. Clin. Med., 11.","DOI":"10.3390\/jcm11247486"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00011-024-01964-8","article-title":"Endocan as a marker of endotheliitis in COVID-19 patients: Modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors","volume":"74","author":"Alves","year":"2025","journal-title":"Inflamm. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"115669","DOI":"10.1016\/j.intimp.2025.115669","article-title":"Resolvin E1-Chemerin receptor 1 axis is dysregulated in critical COVID-19 patients","volume":"167","author":"Martins","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2362.2009.02234.x","article-title":"A catalogue of reporting guidelines for health research","volume":"40","author":"Simera","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_56","unstructured":"WHO (2020). Corticosteroids for COVID-19: Living Guidance, 2 September 2020, World Health Organization. WHO\/2019-nCoV\/Corticosteroids\/2020.1."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Carlini, V., Noonan, D.M., Abdalalem, E., Goletti, D., Sansone, C., Calabrone, L., and Albini, A. (2023). The multifaceted nature of IL-10: Regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1161067"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1189\/jlb.0612293","article-title":"The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications","volume":"93","author":"Shachar","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"106511","DOI":"10.1016\/j.phrs.2022.106511","article-title":"Glucocorticoids and COVID-19","volume":"185","author":"Bruscoli","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Spick, M., Campbell, A., Baricevic-Jones, I., von Gerichten, J., Lewis, H.M., Frampas, C.F., Longman, K., Stewart, A., Dunn-Walters, D., and Skene, D.J. (2022). Multi-Omics Reveals Mechanisms of Partial Modulation of COVID-19 Dysregulation by Glucocorticoid Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012079"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17476348.2023.2177155","article-title":"Safety and efficacy of glucocorticoids in the treatment of COVID-19: A meta-analysis of randomized control trials","volume":"17","author":"Qiao","year":"2023","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10238-024-01405-0","article-title":"Efficacy and safety of glucocorticoids in the treatment of COVID-19: A systematic review and meta-analysis of RCTs","volume":"24","author":"Ye","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"EVIDoa2200283","DOI":"10.1056\/EVIDoa2200283","article-title":"Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen","volume":"2","author":"Covello","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1096\/fj.02-0239fje","article-title":"Aberrant inflammation and resistance to glucocorticoids in annexin 1-\/- mouse","volume":"17","author":"Hannon","year":"2003","journal-title":"FASEB J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1136\/annrheumdis-2011-201180","article-title":"The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis","volume":"71","author":"Patel","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1006\/cyto.1997.0325","article-title":"IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein","volume":"10","author":"Solito","year":"1998","journal-title":"Cytokine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0002-9440(10)62530-8","article-title":"Cytokine modulation of liver annexin 1 expression during experimental endotoxemia","volume":"159","author":"Ajuebor","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.20301","article-title":"Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis","volume":"50","author":"Murphy","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1084\/jem.187.8.1285","article-title":"Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release","volume":"187","author":"Gronert","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"105117","DOI":"10.1016\/j.phrs.2020.105117","article-title":"Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling","volume":"161","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s42003-024-07025-4","article-title":"FPR1 signaling aberrantly regulates S100A8\/A9 production by CD14(+)FCN1(hi) macrophages and aggravates pulmonary pathology in severe COVID-19","volume":"7","author":"Wang","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7669","DOI":"10.4049\/jimmunol.172.12.7669","article-title":"An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family","volume":"172","author":"Ernst","year":"2004","journal-title":"J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1182\/blood-2005-08-3099","article-title":"Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: Indication of distinct receptor involvement","volume":"107","author":"Hayhoe","year":"2006","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Resende, F., Araujo, S., Tavares, L.P., Teixeira, M.M., and Costa, V.V. (2023). The Multifaceted Role of Annexin A1 in Viral Infections. Cells, 12.","DOI":"10.3390\/cells12081131"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"110352","DOI":"10.1016\/j.mehy.2020.110352","article-title":"Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis","volume":"145","author":"Bonavita","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41392-021-00508-4","article-title":"Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"101601","DOI":"10.1016\/j.smim.2022.101601","article-title":"Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7)","volume":"59","author":"Tavares","year":"2022","journal-title":"Semin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"107005","DOI":"10.1016\/j.phrs.2023.107005","article-title":"The Annexin-A1 mimetic RTP-026 promotes acute cardioprotection through modulation of immune cell activation","volume":"198","author":"Chen","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8239258","DOI":"10.1155\/2016\/8239258","article-title":"Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance","volume":"2016","author":"Sugimoto","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.4049\/jimmunol.166.10.6294","article-title":"A potential role for annexin 1 as a physiologic mediator of glucocorticoid-induced L-selectin shedding from myeloid cells","volume":"166","author":"Strausbaugh","year":"2001","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1097-2765(00)80323-8","article-title":"A novel ligand of the formyl peptide receptor: Annexin I regulates neutrophil extravasation by interacting with the FPR","volume":"5","author":"Walther","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4049\/jimmunol.165.3.1573","article-title":"Annexin 1 binds to U937 monocytic cells and inhibits their adhesion to microvascular endothelium: Involvement of the alpha 4 beta 1 integrin","volume":"165","author":"Solito","year":"2000","journal-title":"J. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Peshavariya, H.M., Taylor, C.J., Goh, C., Liu, G.S., Jiang, F., Chan, E.C., and Dusting, G.J. (2013). Annexin peptide Ac2-26 suppresses TNFalpha-induced inflammatory responses via inhibition of Rac1-dependent NADPH oxidase in human endothelial cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060790"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cca.2020.07.041","article-title":"Endocan: A novel biomarker for risk stratification, prognosis and therapeutic monitoring in human cardiovascular and renal diseases","volume":"509","author":"Bessa","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.smim.2015.03.014","article-title":"The resolution of inflammation: Principles and challenges","volume":"27","author":"Headland","year":"2015","journal-title":"Semin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev.pathmechdis.3.121806.151409","article-title":"Anti-inflammatory and proresolving lipid mediators","volume":"3","author":"Serhan","year":"2008","journal-title":"Annu. Rev. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/imm.13455","article-title":"Annexin-A1: The culprit or the solution?","volume":"166","author":"Kelly","year":"2022","journal-title":"Immunology"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Schebb, N.H., Kuhn, H., Kahnt, A.S., Rund, K.M., O\u2019Donnell, V.B., Flamand, N., Peters-Golden, M., Jakobsson, P.J., Weylandt, K.H., and Rohwer, N. (2022). Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far?. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.838782"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1677\/JOE-06-0132","article-title":"The influence of 17beta-estradiol on annexin 1 expression in the anterior pituitary of the female rat and in a folliculo-stellate cell line","volume":"192","author":"Davies","year":"2007","journal-title":"J. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Loiola, R.A., Wickstead, E.S., Solito, E., and McArthur, S. (2019). Estrogen Promotes Pro-resolving Microglial Behavior and Phagocytic Cell Clearance Through the Actions of Annexin A1. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00420"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Liao, W.I., Wu, S.Y., Tsai, S.H., Pao, H.P., Huang, K.L., and Chu, S.J. (2021). 2-Methoxyestradiol Protects Against Lung Ischemia\/Reperfusion Injury by Upregulating Annexin A1 Protein Expression. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.596376"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/ATVBAHA.111.235176","article-title":"Activation of the annexin A1 pathway underlies the protective effects exerted by estrogen in polymorphonuclear leukocytes","volume":"31","author":"Nadkarni","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbi.2015.08.020","article-title":"Estrogen protects the blood-brain barrier from inflammation-induced disruption and increased lymphocyte trafficking","volume":"51","author":"Maggioli","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0002-9440(10)64002-3","article-title":"Neutrophil interaction with inflamed postcapillary venule endothelium alters annexin 1 expression","volume":"158","author":"Oliani","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.bbamcr.2006.08.041","article-title":"Proteolytic cleavage of annexin 1 by human leukocyte elastase","volume":"1763","author":"Rescher","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"29998","DOI":"10.1074\/jbc.M702876200","article-title":"Annexin 1 cleavage in activated neutrophils: A pivotal role for proteinase 3","volume":"282","author":"Vong","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.bcp.2013.02.011","article-title":"Pro-inflammatory and pathogenic properties of Annexin-A1: The whole is greater than the sum of its parts","volume":"85","author":"Piras","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Tsao, F.H., Xiang, Z., Abbasi, A., and Meyer, K.C. (2012). Neutrophil necrosis and annexin 1 degradation associated with airway inflammation in lung transplant recipients with cystic fibrosis. BMC Pulm. Med., 12.","DOI":"10.1186\/1471-2466-12-44"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1189\/jlb.0112008","article-title":"Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis","volume":"92","author":"Vago","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1165\/rcmb.2015-0083OC","article-title":"Inhibition of Phosphodiesterase-4 during Pneumococcal Pneumonia Reduces Inflammation and Lung Injury in Mice","volume":"55","author":"Tavares","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1161\/HYPERTENSIONAHA.123.21348","article-title":"Resolvin E1\/ChemR23 Protects Against Hypertension and Vascular Remodeling in Angiotensin II-Induced Hypertensive Mice","volume":"80","author":"Zhang","year":"2023","journal-title":"Hypertension"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12944-024-02386-5","article-title":"Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics","volume":"23","author":"Molfino","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"106781","DOI":"10.1016\/j.prostaglandins.2023.106781","article-title":"Imbalanced serum levels of resolvin E1 (RvE1) and leukotriene B4 (LTB4) may contribute to the pathogenesis of atherosclerosis","volume":"169","author":"Molaie","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.biochi.2020.08.015","article-title":"Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake","volume":"178","author":"Calder","year":"2020","journal-title":"Biochimie"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1038\/s41467-023-41766-w","article-title":"Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples","volume":"14","author":"Schebb","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1038\/s41467-023-41767-9","article-title":"Reply to: Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples","volume":"14","author":"Dalli","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/4\/508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:47:48Z","timestamp":1775123268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/4\/508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":107,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["biom16040508"],"URL":"https:\/\/doi.org\/10.3390\/biom16040508","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}